Forbes Names SP Plus Corporation to its 2024 List of America’s Most Successful Small-Cap Companies
CHICAGO, Jan. 30, 2024 (GLOBE NEWSWIRE) — SP+® Corporation (SP+), (Nasdaq: SP) a best-in-class technology and operations management provider of […]
Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
JERUSALEM, Jan. 30, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the […]
CorMedix Inc. Announces Commercial and Reimbursement Updates
BERKELEY HEIGHTS, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and […]
RELI Exchange Launches the Client Referral Portal into its Proprietary InsurTech Platform
LAKEWOOD, NJ, Jan. 30, 2024 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: RELI; RELIW) (“Reliance” or the “Company”), today […]
SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application
SANTA CLARA, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) — SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated […]
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
MINNEAPOLIS, Jan. 30, 2024 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics […]
Franklin Electric Schedules Its Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call
FORT WAYNE, Ind., Jan. 30, 2024 (GLOBE NEWSWIRE) — Franklin Electric Co., Inc. (NASDAQ: FELE) will release its fourth quarter […]
Sensus Healthcare to Host Fourth Quarter and Full Year 2023 Financial Results and Business Update Conference Call on Thursday, February 8, 2024
BOCA RATON, Fla. , Jan. 30, 2024 (GLOBE NEWSWIRE) — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing […]
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program
The Phase II clinical trial in patients with Alzheimer’s disease with neuroinflammation is on track to complete enrollment mid-2024 with […]
Motus GI Holdings Publishes Positive Results from a European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with a History of Poor Bowel Preparation
FORT LAUDERDALE, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc. (Nasdaq: MOTS, or “Motus GI” or “the […]
